Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Nov 13, 2026
Read MoreZai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Nov 13, 2026
Read MoreZai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
Nov 05, 2026
Read MoreZai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Nov 05, 2026
Read MoreZai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Oct 23, 2026
Read MoreZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Oct 21, 2026
Read More